183 related articles for article (PubMed ID: 37168878)
1. Incidence of Bone Metastases and Skeletal-Related Events in Patients With
Brouns AJWM; van Veelen A; Veerman GDM; Steendam C; Dursun S; van der Leest C; Croes S; Dingemans AC; Hendriks LEL
JTO Clin Res Rep; 2023 May; 4(5):100513. PubMed ID: 37168878
[TBL] [Abstract][Full Text] [Related]
2. Osimertinib for
Xie L; Nagpal S; Wakelee HA; Li G; Soltys SG; Neal JW
Oncologist; 2019 Jun; 24(6):836-843. PubMed ID: 30126856
[TBL] [Abstract][Full Text] [Related]
3. Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status.
Lee J; Choi Y; Han J; Park S; Jung HA; Su JM; Lee SH; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2020 Nov; 15(11):1758-1766. PubMed ID: 32652216
[TBL] [Abstract][Full Text] [Related]
4. Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations.
Nagata M; Kudoh S; Mitsuoka S; Suzumura T; Umekawa K; Tanaka H; Matsuura K; Kimura T; Yoshimura N; Hirata K
Osaka City Med J; 2013 Jun; 59(1):45-52. PubMed ID: 23909080
[TBL] [Abstract][Full Text] [Related]
5. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
[TBL] [Abstract][Full Text] [Related]
6. Overall Survival Improvement in Patients with Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer and Bone Metastasis Treated with Denosumab.
Ko HW; Chiu CT; Wang CL; Yang TY; Liu CY; Yu CT; Tseng LC; Kuo CS; Wang CC; Yang MH; Yang CT
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884531
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).
Cardona AF; Ruiz-Patiño A; Recondo G; Martín C; Raez L; Samtani S; Minata JN; Blaquier JB; Enrico D; Burotto M; Ordóñez-Reyes C; Chamorro DF; Garcia-Robledo JE; Corrales L; Zatarain-Barrón ZL; Más L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Mejía S; Jaller E; Vargas C; Carranza H; Otero J; Rodríguez J; Archila P; Bermudez M; Gamez T; Cordeiro de Lima V; Freitas H; Russo A; Polo C; Malapelle U; Perez DM; Rolfo C; Viola L; Rosell R; Arrieta O
Clin Lung Cancer; 2022 Sep; 23(6):522-531. PubMed ID: 35798634
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.
Gen S; Tanaka I; Morise M; Koyama J; Kodama Y; Matsui A; Miyazawa A; Hase T; Hibino Y; Yokoyama T; Kimura T; Yoshida N; Sato M; Hashimoto N
BMC Cancer; 2022 Jun; 22(1):654. PubMed ID: 35698083
[TBL] [Abstract][Full Text] [Related]
9. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.
Ulas A; Bilici A; Durnali A; Tokluoglu S; Akinci S; Silay K; Oksuzoglu B; Alkis N
Tumour Biol; 2016 Jan; 37(1):1131-40. PubMed ID: 26276360
[TBL] [Abstract][Full Text] [Related]
11. High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases.
Laganà M; Gurizzan C; Roca E; Cortinovis D; Signorelli D; Pagani F; Bettini A; Bonomi L; Rinaldi S; Berardi R; Filetti M; Giusti R; Pilotto S; Milella M; Intagliata S; Baggi A; Cortellini A; Soto Parra H; Brighenti M; Petrelli F; Bennati C; Bidoli P; Garassino MC; Berruti A
Front Oncol; 2020; 10():588862. PubMed ID: 33282740
[TBL] [Abstract][Full Text] [Related]
12. Osimertinib in NSCLC With Atypical
Ji J; Aredo JV; Piper-Vallillo A; Huppert L; Rotow JK; Husain H; Stewart S; Cobb R; Wakelee HA; Blakely CM; Wong ML; Gubens MA; Madani MH; Digumarthy SR; McCoach C; Piotrowska Z; Neal JW; Riess JW
JTO Clin Res Rep; 2023 Mar; 4(3):100459. PubMed ID: 36879929
[TBL] [Abstract][Full Text] [Related]
13. Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer.
Auliac JB; Saboundji K; Andre M; Madelaine J; Quere G; Masson P; Vergnenegre A; Lamy R; Raymond S; Chiappa AM; Hauss PA; Fournel P; Corre R; Chouaid C
Target Oncol; 2019 Jun; 14(3):307-314. PubMed ID: 31119481
[TBL] [Abstract][Full Text] [Related]
14. A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.
Cheema P; Cho BC; Freitas H; Provencio M; Chen YM; Kim SW; Wu YL; Passaro A; Martin C; Tiseo M; Chang GC; Park K; Solomon B; Burghuber O; Laskin J; Wang Z; Lee SY; Hu Y; Vansteenkiste J; Zhang HL; Hanrahan E; Geldart T; Taylor R; Servidio L; Li J; Marinis F
Future Oncol; 2023 Jan; 19(1):61-75. PubMed ID: 36656302
[TBL] [Abstract][Full Text] [Related]
15. Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec.
Agulnik JS; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Small D
Curr Oncol; 2021 Dec; 28(6):5179-5191. PubMed ID: 34940073
[TBL] [Abstract][Full Text] [Related]
16. Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach.
Jacobson D; Cadieux B; Higano CS; Henry DH; Bachmann BA; Rehn M; Stopeck AT; Saad H
J Bone Oncol; 2022 Jun; 34():100423. PubMed ID: 35378840
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.
Saboundji K; Auliac JB; Pérol M; François G; Janicot H; Marcq M; Dubos-Arvis C; Renault A; Guisier F; Odier L; Gervais R; Chouaïd C
Target Oncol; 2018 Aug; 13(4):501-507. PubMed ID: 30039345
[TBL] [Abstract][Full Text] [Related]
18. Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance.
Ma J; Tan SH; Yin DXC; Tran NTA; Tan GS; Lai GGY; Ang MK; Kanesvaran R; Jain A; Rajasekaran T; Tan EH; Lim TKH; Tan DS; Lim DW; Ng QS; Tan WL
Transl Lung Cancer Res; 2023 Apr; 12(4):742-753. PubMed ID: 37197627
[TBL] [Abstract][Full Text] [Related]
19. Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.
Kraskowski O; Stratmann JA; Wiesweg M; Eberhardt W; Metzenmacher M; Schmid KW; Herold T; Schildhaus HU; Darwiche K; Aigner C; Stuschke M; Laue K; Zaun G; Kasper S; Hense J; Sebastian M; Schuler M; Pogorzelski M
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9243-9252. PubMed ID: 37198447
[TBL] [Abstract][Full Text] [Related]
20. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]